abstract |
Novel aminoindazolylurea derivatives of the formula I (I), in which R 1 , R 2 , R 3 , R 4 , R 5 , X and Y have the meanings indicated in Claim 1 , are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type. |